First human tests begin for experimental diabetes drug
NCT ID NCT07242469
Summary
This early-stage study aims to check the safety and side effects of a new experimental medicine called MK-1403 in people with type 2 diabetes. Researchers will give the drug to 52 participants and closely monitor how their bodies handle it and if it affects a blood marker linked to inflammation. The main goal is to see if the drug is safe and well-tolerated before testing if it can help control diabetes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Pharma CR, LLC ( Site 0003)
RECRUITINGMiami, Florida, 33147, United States
Contact Phone: •••-•••-••••
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005)
RECRUITINGSpringfield, Missouri, 65802, United States
Contact Phone: •••-•••-••••
-
ProSciento Inc. ( Site 0001)
RECRUITINGChula Vista, California, 91911, United States
Contact Phone: •••-•••-••••
-
QPS-MRA, LLC ( Site 0004)
RECRUITINGMiami, Florida, 33143, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.